Bristol-Myers to Acquire Flexus Immunotherapy Pipeline

Bristol-Myers Squibb agreed to acquire privately-held biotechnology company Flexus in a deal potentially valued at up to $1.25 billion that gives Bristol access to a pipeline of investigational immunotherapy treatments.



from WSJ.com: US Business http://ift.tt/1JCZAJg

via IFTTT